There are plenty of reasons to buy a leading biopharma business like AbbVie (NYSE: ABBV), and investors just got at least a few more. Thanks to a large acquisition that came out of left field, it could now become a prominent psychiatric-drug company. Though the area isn’t traditionally in AbbVie’s wheelhouse, there’s reason to believe […]
By almost any measure, AbbVie (NYSE: ABBV) shares should have risen Friday. The pharmaceutical giant delivered first-quarter sales and earnings results that topped estimates. The decline in sales of multi-indication immunosuppressive drug Humira — a natural result of its loss of patent exclusivity — is taking shape at a slower pace than was initially feared. […]
AbbVie (ABBV) is “firing on all cylinders,” an analyst said Friday after the pharma giant beat Wall Street’s first-quarter expectations and raised its earnings outlook. But AbbVie stock tumbled. X Humira remains AbbVie’s biggest moneymaker despite facing competition from biosimilars in the U.S. and abroad. Humira treats immunological conditions like arthritis and psoriasis. During the […]
By Leroy Leo and Christy Santhosh (Reuters) -AbbVie raised its annual profit forecast on Friday after strong sales of its immunology drug Skyrizi and cancer drug Imbruvica helped the company beat Wall Street estimates for the first quarter. Shares of AbbVie rose nearly 2.5% in premarket trading. The company now expects adjusted profit of between […]
AbbVie (ABBV) stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, inflammation drug Humira. X According to data collected by Iqvia, the number of prescriptions of Novartis‘ (NVS) Hyrimoz has “stepped up dramatically in recent weeks,” Leerink Partners analyst David Risinger said in a […]
What’s Going On AbbVie Stock On Friday? Friday, AbbVie Inc (NYSE:ABBV) released an interim analysis of an ongoing Phase 3, open-label 156-week extension study evaluating the long-term safety and tolerability of oral atogepant for the prevention of migraine in participants with chronic or episodic migraine. The shares are trading lower with a session volume of 3.9 million versus […]
Income-seeking investors usually don’t think of the innovation-dependent pharmaceutical industry as a place to look for businesses with reliable cash flows. Dividend seekers have a good reason to be cautious regarding drugmaker stocks. Profit driven by patent-protected market exclusivity can disappear in the blink of an eye after those patents expire. Image source: Getty Images. […]
(Reuters) – AbbVie Inc beat Wall Street estimates for fourth-quarter profit on Friday, helped by a smaller-than-expected decline in sales of its blockbuster drug, Humira, and strong demand for Botox amid stiff competition. Investors have been keeping a close eye on falling sales of arthritis drug Humira, which was until recently the world’s top-selling treatment. […]
dividends Dividend stocks can offer a valuable source of income for investors who want to diversify their portfolios. However, investors should also be aware that most of these stocks will gradually decline in value over time unless the dividend is reinvested. This may seem surprising, but ample evidence supports this claim. Only a few dividend […]